Physician Insights on Transitioning Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy From Intravenous Immunoglobulin to Subcutaneous Efgartigimod PH20 (P7-9.016)

Neurology 2026

View at publisher
Authors: Mario Vukic, Kettia Alusma-Hibbert, Amro Stino, Simon Oh, Jamie Aldridge
DOI: 10.1212/wnl.0000000000215937
Cited by: 1

Abstract

To report expert insight on transitioning patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) from intravenous immunoglobulin (IVIg) to subcutaneous (SC) efgartigimod PH20 (co-formulated with recombinant human hyaluronidase PH20).

Fields of Study & Subjects

Peripheral Neuropathies and Disorders Multiple Sclerosis Research Studies Adolescent and Pediatric Healthcare

Publication details

Journal / source
Neurology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
106
Issue
11_Supplement_1
Publication date
9 June 2026
Language
EN